AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

HUMA · NASDAQ · Biotechnology

Humacyte

Commercializing Symvess while expanding its ATEV vessel platform.

$0.6557

After-hours close+0.01 (+0.83%)

At close$0.6503(−6.12%)

Something off on this page? Send us feedback.

Profile

Humacyte, Inc.HUMAHealth Care

Sells Symvess for urgent vascular trauma and develops ATEV tissue vessels for dialysis access and other vascular uses. Revenue is concentrated in Symvess, with uptake shaped by trauma-center adoption, reimbursement, safety monitoring, and access to capital.

Commercializes Symvess, an acellular tissue engineered vessel for adults with extremity arterial injury when urgent revascularization is needed and autologous vein graft is not feasible. The same ATEV platform is being developed for dialysis access, PAD, CABG, pediatric heart surgery, and other tissue or cell-delivery uses.

Operates from Durham under consolidated segment reporting and a manufacturing-led model. U.S. launch work is focused on trauma centers, hospital value-analysis adoption, surgeon demand, reimbursement, and VA access.

Executes around founder-scientist continuity and scaled production of off-the-shelf human tissues. The business depends on Symvess uptake, additional indications, FDA postmarketing safety work around graft failure and infection, and continued access to capital.

Company facts

CEOLaura E. Niklason, M.D., Ph.D.

ListedAug 27, 2021

ExchangeNASDAQ

HeadquartersDurham, NC

CountryUnited States

Employees184

CIK0001818382

ISINUS44486Q1031

Key statistics

Market cap$109.2M

EPS (ttm)−$0.5090

P/E (ttm)−1.28

ROE-938.2%

P/B4.87

P/S51.49

Dividend yield—

Beta3.22vs XLV 0.51

Year to date −33.6% · Average volume (30d) 7.4M

Analysts

Price target, next 12 months$2.00+207.7%Median of 11 analysts · vs the Aug 28 close

ConsensusBuy10 of 11 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $0.6500

High$2.00+207.7%

Median$2.00+207.7%

Low$2.00+207.7%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 12, 2026	BTIG	Reiterate	Buy	$10	$2
Dec 1, 2025	H.C. Wainwright	Target			$3
Oct 13, 2025	UBS	Target			$6

Earnings

EPS

Estimate−$0.09

ReportedDue Nov 11, 2026

Revenue

Estimate$769.4K

ReportedDue Nov 11, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 12, 2026Q2 FY26	−$0.11	−$0.16	−41.0%	$1.0M	$406.0K	−61.0%	−6.34%
May 13, 2026Q1 FY26	−$0.10	−$0.09	+10.0%	$1.5M	$495.0K	−66.2%	−11.50%
Mar 27, 2026Q4 FY25	−$0.13	−$0.13	0.0%	$1.3M	$467.0K	−65.4%	−14.96%
Nov 12, 2025Q3 FY25	−$0.17	−$0.14	+17.6%	$1.3M	$753.0K	−44.2%	−4.80%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$517.0K	$301.0K	$753.0K	$467.0K	$495.0K	$406.0K
Gross profit	−$1.5M	−$1.8M	−$1.4M	−$10.4M	−$1.5M	−$825.0K
Operating income	−$23.2M	−$29.7M	−$24.4M	−$30.8M	−$28.9M	−$27.0M
Net income	$39.1M	−$37.7M	−$17.5M	−$24.8M	−$17.6M	−$36.8M
Diluted EPS	$0.28	−$0.24	−$0.11	−$0.15	−$0.09	−$0.16
Gross margin	-282.8%	-588.7%	-182.2%	-2,227.6%	-311.7%	-203.2%
Operating margin	-4,484.3%	-9,876.1%	-3,239.0%	-6,603.0%	-5,845.5%	-6,649.3%

Fiscal years (4-quarter sums)FY21 $1.3M · FY22 $1.6M · FY23 $0 · FY24 $7.2M · FY25 $2.0M

Revenue by product · Q1 FY26

Product$493.0K · 100%

Product And Service, Other$2.0K · 0%

Balance sheet, Jun 30, 2026Cash & short-term investments $79.9M · Total debt $66.2M · Total assets $138.1M · Shareholders' equity $31.3M

Dividends

No dividends on record.

Ownership

Institutions 44.42%74.63M sharesInsiders 0.65%1.09M sharesOther 54.93%92.28M shares

Shares outstanding 168.00M · Float 138.12M · 82.2% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Vanguard Capital Management LLC	10.11M	6.02%	13F	Aug 13, 2026
Antipodes Partners Ltd	10.10M	6.01%	13F	Aug 6, 2026
Alyeska Investment Group, L.P.	6.02M	3.59%	13F	Aug 14, 2026
Davidson Kempner Capital Management LP	5.00M	2.98%	13F	Aug 14, 2026
BlackRock, Inc.	4.84M	2.88%	13F	Aug 7, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 20, 2026	Keith Anthony Jones	director	+10,000	$0.6930
Aug 17, 2026	Keith Anthony Jones	director	+30,000	$0.5940
May 18, 2026	Shamik J. Parikh	officer: Chief Medical Officer	−45,887	$0.8967
May 18, 2026	Dale A. Sander	officer: CFO and Chief Corp. Dev. Off	−45,887	$0.8967
May 18, 2026	Michael T. Constantino	director	+11,000	$0.8945